Fulton Zachary W, Boothby Benjamin C, Phillips Seth A
Orthopaedic Surgery, Mercy Health Saint Vincent Medical Center, Toledo, USA.
Cureus. 2022 Aug 27;14(8):e28474. doi: 10.7759/cureus.28474. eCollection 2022 Aug.
While amputation techniques have improved over time, questions remain around how to best treat neuromas and severed nerves in the amputee population, specifically for trauma-related amputees. This systematic review investigates and summarizes outcomes following targeted muscle reinnervation (TMR) for the trauma-related amputee population. Studies were classified based on primary or secondary TMR and relevant outcomes, including the ability to use a prosthesis, post-TMR opioid use, Patient-Reported Outcomes Measurement Information System (PROMIS) scores for phantom limb pain and residual limb pain, and overall pain resolution/reduction. Following TMR for trauma-related amputation, most patients experienced neuroma pain resolution (86.2%, 95% confidence interval [CI]: 67.2-95.0%) and overall pain reduction/resolution (90.7%, 95% CI: 82.2-95.4%). No differences were seen between primary and secondary TMR. Preliminary evidence indicates that TMR is effective for preventing or treating pain in patients with trauma-related amputation, whether used in the acute or delayed setting.
尽管截肢技术随着时间推移有所改进,但对于如何最好地治疗截肢人群中的神经瘤和离断神经,尤其是创伤相关截肢者,仍存在问题。本系统评价调查并总结了针对创伤相关截肢人群进行靶向肌肉再支配(TMR)后的结果。研究根据原发性或继发性TMR以及相关结果进行分类,包括使用假肢的能力、TMR后阿片类药物的使用情况、患者报告结局测量信息系统(PROMIS)中幻肢痛和残肢痛的评分,以及总体疼痛缓解/减轻情况。对于创伤相关截肢进行TMR后,大多数患者的神经瘤疼痛得到缓解(86.2%,95%置信区间[CI]:67.2 - 95.0%),总体疼痛减轻/缓解(90.7%,95%CI:82.2 - 95.4%)。原发性和继发性TMR之间未观察到差异。初步证据表明,TMR对于预防或治疗创伤相关截肢患者的疼痛是有效的,无论在急性期还是延迟期使用。